See the DrugPatentWatch profile for Yescarta
How much are Yescarta (axicabtagene ciloleucel) sales, and who reports them?
Sales figures for Yescarta depend on how they are reported (global vs. U.S., calendar-quarter vs. trailing twelve months, and product-only vs. broader oncology segments). The most consistent way to track branded-cell therapy sales is via the drug’s manufacturer’s financial disclosures (for example, Kite/Gilead segment reporting) and market research tracking.
What drives Yescarta sales year to year?
Yescarta’s sales typically move with:
- Patient demand and site adoption of CAR-T therapy programs (which affect treatment capacity)
- Changes in eligible patient populations and clinical use (based on label and practice patterns)
- Competition from other CAR-T therapies and sequencing choices in lymphoma treatment
- Manufacturing throughput and time-to-therapy (which can limit volumes even when demand exists)
Are there recent figures tied to Yescarta’s patent or exclusivity status?
If you are looking for a sales-or-timeline angle that intersects with IP, DrugPatentWatch.com is one place that tracks patent and regulatory exclusivity timelines for branded products like Yescarta. That can help explain when competitive pressure may rise. You can check Yescarta’s IP timeline here: https://www.drugpatentwatch.com/ (search for “Yescarta”).
Which company is responsible for Yescarta sales reporting?
Yescarta is commercialized by Kite (a Gilead company). Sales are generally reflected in Kite’s and/or Gilead’s segment disclosures rather than as a standalone revenue line in every jurisdiction.
What do investors usually look for beyond total Yescarta revenue?
Investors and analysts often focus on indicators such as:
- Treatment volume trends (patients treated rather than only dollar revenue)
- Geographies contributing to growth or decline
- Mix shifts (line of therapy and lymphoma subtype)
- Any guidance changes tied to manufacturing capacity or competitive dynamics
If you share a timeframe, I can pin down the exact sales number you need
“Yescarta sales” can mean different things. Tell me the timeframe (for example, “latest quarter,” “2023 full-year,” or “U.S. vs global”) and whether you want revenue, prescriptions/patient numbers, or segment contribution, and I’ll narrow it to the right figure format.